Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Janssen Research & Development, LLC
AVEO Pharmaceuticals, Inc.
Alliance for Clinical Trials in Oncology
Sun Yat-sen University
Mayo Clinic
West China Hospital
Merus B.V.
Merus B.V.
Eastern Cooperative Oncology Group
Sun Yat-sen University
Sun Yat-sen University
First Affiliated Hospital of Guangxi Medical University
Johnson & Johnson Enterprise Innovation Inc.
Sun Yat-sen University
Affiliated Hospital of Guangdong Medical University
Centre Francois Baclesse
Universität des Saarlandes
Fudan University
Fudan University
European Organisation for Research and Treatment of Cancer - EORTC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shanghai Miracogen Inc.
Shandong Cancer Hospital and Institute
Shandong Cancer Hospital and Institute
Sun Yat-sen University
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Brown University
Fudan University
Sun Yat-sen University
Radboud University Medical Center
Centre Leon Berard
Vanderbilt University Medical Center
Rakuten Medical, Inc.
Centre Francois Baclesse
GlaxoSmithKline
University of California, San Francisco
Sun Yat-sen University
Sunnybrook Health Sciences Centre
Fudan University
Sun Yat-sen University
Eye & ENT Hospital of Fudan University
UNICANCER
Eye & ENT Hospital of Fudan University
Shandong Cancer Hospital and Institute